中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(9): 2144-2147

Correlation of serum alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, and alkaline phosphatase with blood pressure in patients with nonalcoholic fatty liver disease in coastal regions of Shandong Province in China

DOI: 10.3969/j.issn.1001-5256.2021.09.027
  • a.

    Department of Infectious Diseases, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong 266011, China

  • b.

    Clinical Research Center, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong 266011, China

Research funding:

National Natural Science Foundation of China (31770837)

  • Received Date: 2021-02-22
  • Accepted Date: 2021-03-10
  • Published Date: 2021-09-20
    Abstract
  •   Objective  To investigate whether there was a correlation between serum liver enzyme levels and blood pressure in the Chinese Han population with nonalcoholic fatty liver disease (NAFLD) in Shandong coastal regions in China.  Methods  A total of 269 NAFLD patients who lived in Shandong coastal regions and attended or underwent physical examination in Qingdao Municipal Hospital from December 2019 to June 2020 were enrolled, among whom 105 had hypertension and 164 did not have hypertension. Morning blood pressure was measured to calculate mean arterial pressure (MAP), and laboratory tests were performed to measure the serum levels of liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP)] and fasting blood glucose (FBG). The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. A Pearson correlation analysis was used to investigate the correlation of four liver enzymes with the indices including MAP, and a binary logistic regression model was used to analyze the impact of serum liver enzymes on hypertension.  Results  Compared with the non-hypertension group, the hypertension group had significantly higher body mass index (BMI), MAP, and GGT (all P < 0.05). For all NAFLD patients and the NAFLD patients without hypertension, male patients had significantly higher BMI, MAP, ALT, AST, and GGT than female patients (all P < 0.05), and for the NAFLD patients with hypertension, male patients had a significantly higher level of GGT than female patients (P < 0.05). There was a significant difference in the distribution of GGT between the hypertension group and the non-hypertension group, and compared with the non-hypertension group, the hypertension group had a significantly higher proportion of patients with GGT exceeding the normal range (χ2=4.781, P=0.029). Serum GGT level was correlated with MAP within the normal range (70-105 mm Hg) (r=0.178, P=0.011), while there was no significant correlation when MAP exceeded the normal range (P=0.415). After adjustment for age and sex, the binary logistic regression model showed that AST level was positively associated with hypertension in the population with NAFLD (odds ratio [OR]=1.011, 95% confidence interval [CI]: 1.000-1.022, P=0.040), and after further adjustment for BMI and FBG, the results showed that AST level was still positively associated with hypertension (OR=1.011, 95% CI: 1.000-1.022, P=0.044).  Conclusion  In Chinese Han population with NAFLD in Shandong coastal regions, higher levels of AST may predict an increased risk of hypertension.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    ESTES C, RAZAVI H, LOOMBA R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1): 123-133. DOI: 10.1002/hep.29466.
    [2]
    COTTER TG, RINELLA M. NAFLD 2020: The state of the disease[J]. Gastroenterology, 2020, 158(7): 1851-1864. DOI: 10.1053/j.gastro.2020.01.052.
    [3]
    BYRNE CD, TARGHER G. NAFLD: A multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): s47-s64. DOI: 10.1016/j.jhep.2014.12.012.
    [4]
    LIU P, TANG Y, GUO X, et al. Bidirectional association between nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study[J]. J Am Soc Hypertens, 2018, 12(9): 660-670. DOI: 10.1016/j.jash.2018.06.013.
    [5]
    ANENI EC, ONI ET, MARTIN SS, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk[J]. J Hypertens, 2015, 33(6): 1207-1214. DOI: 10.1097/HJH.0000000000000532.
    [6]
    WANG Z, CHEN Z, ZHANG L, et al. Status of hypertension in China: Results from the China hypertension survey, 2012-2015[J]. Circulation, 2018, 137(22): 2344-2356. DOI: 10.1161/CIRCULATIONAHA.117.032380.
    [7]
    LEWINGTON S, LACEY B, CLARKE R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China[J]. JAMA Intern Med, 2016, 176(4): 524-532. DOI: 10.1001/jamainternmed.2016.0190.
    [8]
    KOKUBO Y, MATSUMOTO C. Hypertension is a risk factor for several types of heart disease: Review of prospective studies[J]. Adv Exp Med Biol, 2017, 956: 419-426. DOI: 10.1007/5584_2016_99.
    [9]
    LI Z, LIU X, ZHANG Z, et al. Epidemiology of hypertension in a typical state-level poverty-stricken county in China and evaluation of a whole population health prevention project intervention[J]. Int J Hypertens, 2019, 2019: 4634823. DOI: 10.1155/2019/4634823.
    [10]
    CLARK JM, BRANCATI FL, DIEHL AM. The prevalence and etiology of elevated aminotransferase levels in the United States[J]. Am J Gastroenterol, 2003, 98(5): 960-967. DOI: 10.1111/j.1572-0241.2003.07486.x.
    [11]
    HANLEY AJ, WILLIAMS K, FESTA A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: The insulin resistance atherosclerosis study[J]. Diabetes, 2004, 53(10): 2623-2632. DOI: 10.2337/diabetes.53.10.2623.
    [12]
    CLARK JM, DIEHL AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis[J]. JAMA, 2003, 289(22): 3000-3004. DOI: 10.1001/jama.289.22.3000.
    [13]
    KUNUTSOR SK, APEKEY TA, KHAN H. Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies[J]. Atherosclerosis, 2014, 236(1): 7-17. DOI: 10.1016/j.atherosclerosis.2014.06.006.
    [14]
    LEE DH, JACOBS DR Jr, GROSS M, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: The coronary artery risk development in young Adults (CARDIA) study[J]. Clin Chem, 2003, 49(8): 1358-1366. DOI: 10.1373/49.8.1358.
    [15]
    ONAT A, CAN G, ÖRNEK E, et al. Serum γ-glutamyltransferase: Independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease[J]. Obesity (Silver Spring), 2012, 20(4): 842-848. DOI: 10.1038/oby.2011.136.
    [16]
    Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, et al. Guideline for primary care of hypertension(2019)[J]. Chin J Gen Pract, 2019, 18(4): 301-313. DOI: 10.3760/cma.j.issn.1671-7368.2019.04.002.

    中华医学会, 中华医学杂志社, 中华医学会全科医学分会, 等. 高血压基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019, 18(4): 301-313. DOI: 10.3760/cma.j.issn.1671-7368.2019.04.002.
    [17]
    Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for Management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26(2): 120-124. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201903008.htm

    中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26(2): 120-124. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201903008.htm
    [18]
    STRANGES S, TREVISAN M, DORN JM, et al. Body fat distribution, liver enzymes, and risk of hypertension: Evidence from the Western New York Study[J]. Hypertension, 2005, 46(5): 1186-1193. DOI: 10.1161/01.HYP.0000185688.81320.4d.
    [19]
    ZHU Y, GONG Y, ZHU R, et al. Relationship between serum gamma-glutamyltransferase levels and prehypertension in Chinese adults: The cardiometabolic risk in Chinese study[J]. J Clin Hypertens (Greenwich), 2014, 16(10): 760-765. DOI: 10.1111/jch.12381.
    [20]
    HONG X, WONGTONGKAM N, WARD PR, et al. An association of serum ALT with elevated blood pressure in senior adults: A case-control study[J]. Clin Exp Hypertens, 2016, 38(8): 691-695. DOI: 10.1080/10641963.2016.1200608.
    [21]
    RAHMAN S, ISLAM S, HAQUE T, et al. Association between serum liver enzymes and hypertension: A cross-sectional study in Bangladeshi adults[J]. BMC Cardiovasc Disord, 2020, 20(1): 128. DOI: 10.1186/s12872-020-01411-6.
    [22]
    GUO T, HU B, YI WM, et al. Research advances in the serological diagnosis of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(11): 2579-2583. DOI: 10.3969/j.issn.1001-5256.2020.11.041.

    郭滔, 胡波, 易为民, 等. 血清学诊断非酒精性脂肪性肝病的研究进展[J]. 临床肝胆病杂志, 2020, 36(11): 2579-2583. DOI: 10.3969/j.issn.1001-5256.2020.11.041.
    [23]
    ORE A, AKINLOYE OA. Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease[J]. Medicina (Kaunas), 2019, 55(2): 10.3390/medicina55020026. http://www.preprints.org/manuscript/201809.0268/v1/download
    [24]
    JIANG YZ, NIE HM, WANG R. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2019, 35(11): 2588-2591. DOI: 10.3969/j.issn.1001-5256.2019.11.044.

    姜煜资, 聂红明, 汪蓉. 非酒精性脂肪性肝病的发病机制[J]. 临床肝胆病杂志, 2019, 35(11): 2588-2591. DOI: 10.3969/j.issn.1001-5256.2019.11.044.
    [25]
    TOUYZ RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance?[J]. Hypertension, 2004, 44(3): 248-252. DOI: 10.1161/01.HYP.0000138070.47616.9d.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (546) PDF downloads(42) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return